ATE439355T1 - 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren - Google Patents
2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatorenInfo
- Publication number
- ATE439355T1 ATE439355T1 AT06769822T AT06769822T ATE439355T1 AT E439355 T1 ATE439355 T1 AT E439355T1 AT 06769822 T AT06769822 T AT 06769822T AT 06769822 T AT06769822 T AT 06769822T AT E439355 T1 ATE439355 T1 AT E439355T1
- Authority
- AT
- Austria
- Prior art keywords
- iap
- diaza
- aminocarbonyl
- modulators
- cyclic compounds
- Prior art date
Links
- -1 AMINOCARBONYL-SUBSTITUTED PIPERAZINE Chemical class 0.000 title 1
- 230000006907 apoptotic process Effects 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005017116A DE102005017116A1 (de) | 2005-04-13 | 2005-04-13 | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
| PCT/US2006/013943 WO2006113376A1 (en) | 2005-04-13 | 2006-04-13 | 2 -aminocarbonyl substituted piperazine or diaza-cyclic compounds as apoptosis protein inhibitor (iap) modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE439355T1 true ATE439355T1 (de) | 2009-08-15 |
Family
ID=36829712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06769822T ATE439355T1 (de) | 2005-04-13 | 2006-04-13 | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7932255B2 (de) |
| EP (1) | EP1874748B1 (de) |
| JP (1) | JP2008536861A (de) |
| KR (1) | KR20070119088A (de) |
| CN (1) | CN101160297B (de) |
| AT (1) | ATE439355T1 (de) |
| AU (1) | AU2006236714A1 (de) |
| BR (1) | BRPI0608783A2 (de) |
| CA (1) | CA2604821A1 (de) |
| DE (2) | DE102005017116A1 (de) |
| ES (1) | ES2328405T3 (de) |
| MX (1) | MX2007012703A (de) |
| PL (1) | PL1874748T3 (de) |
| PT (1) | PT1874748E (de) |
| RU (1) | RU2007141578A (de) |
| WO (1) | WO2006113376A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772177B2 (en) | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
| BRPI0617751A2 (pt) | 2005-10-25 | 2011-08-02 | Aegera Therapeutics Inc | compostos de ligação do domìnio iap bir |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| EP2024362A4 (de) | 2006-05-16 | 2012-01-25 | Pharmascience Inc | An die iap-bir-domäne bindende verbindungen |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
| PH12012501813A1 (en) | 2010-02-12 | 2012-12-10 | Pharmascience Inc | Iap bir domain binding compounds |
| ES2652454T3 (es) * | 2011-03-16 | 2018-02-02 | Shanghai Pharmaceuticals Holding Co., Ltd. | Compuesto heterocíclico saturado que contiene nitrógeno |
| US10875851B2 (en) | 2016-11-18 | 2020-12-29 | Merck Sharp & Dohme Corp. | Factor XIIa inhibitors |
| CN107879997B (zh) * | 2017-12-25 | 2021-01-26 | 三峡大学 | 一种小分子抑制剂sld1338及其在制药中的应用 |
| CN112533898A (zh) * | 2018-07-31 | 2021-03-19 | 日商泛美克斯股份有限公司 | 杂环化合物 |
| EP4006037A4 (de) | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | Heterocyclische verbindung |
| WO2023215205A1 (en) * | 2022-05-06 | 2023-11-09 | Merck Sharp & Dohme Llc | Orexin receptor agonists |
| WO2024107615A1 (en) * | 2022-11-17 | 2024-05-23 | Merck Sharp & Dohme Llc | Orexin receptor agonists |
| WO2025090605A1 (en) * | 2023-10-24 | 2025-05-01 | University Of Houston System | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| ID27002A (id) * | 1998-03-19 | 2001-02-22 | Vertex Pharma | Penghambat-penghambat kaspase |
| WO2000039119A1 (en) * | 1998-12-23 | 2000-07-06 | Schering Corporation | Novel inhibitors of farnesyl-protein transferase |
| AU2002257114A1 (en) * | 2001-04-06 | 2002-10-21 | Schering Corporation | Treatment of malaria with farsenyl protein transferase inhibitors |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| JP4541882B2 (ja) | 2002-07-02 | 2010-09-08 | ノバルティス アーゲー | Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤 |
-
2005
- 2005-04-13 DE DE102005017116A patent/DE102005017116A1/de not_active Withdrawn
-
2006
- 2006-04-13 RU RU2007141578/04A patent/RU2007141578A/ru not_active Application Discontinuation
- 2006-04-13 CA CA002604821A patent/CA2604821A1/en not_active Abandoned
- 2006-04-13 EP EP06769822A patent/EP1874748B1/de not_active Not-in-force
- 2006-04-13 KR KR1020077026234A patent/KR20070119088A/ko not_active Withdrawn
- 2006-04-13 PL PL06769822T patent/PL1874748T3/pl unknown
- 2006-04-13 PT PT06769822T patent/PT1874748E/pt unknown
- 2006-04-13 ES ES06769822T patent/ES2328405T3/es active Active
- 2006-04-13 JP JP2008506709A patent/JP2008536861A/ja active Pending
- 2006-04-13 CN CN2006800125373A patent/CN101160297B/zh not_active Expired - Fee Related
- 2006-04-13 MX MX2007012703A patent/MX2007012703A/es not_active Application Discontinuation
- 2006-04-13 WO PCT/US2006/013943 patent/WO2006113376A1/en active Application Filing
- 2006-04-13 US US11/911,418 patent/US7932255B2/en not_active Expired - Fee Related
- 2006-04-13 AT AT06769822T patent/ATE439355T1/de active
- 2006-04-13 BR BRPI0608783-3A patent/BRPI0608783A2/pt not_active IP Right Cessation
- 2006-04-13 DE DE602006008447T patent/DE602006008447D1/de active Active
- 2006-04-13 AU AU2006236714A patent/AU2006236714A1/en not_active Abandoned
-
2011
- 2011-03-21 US US13/053,046 patent/US20110183955A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101160297B (zh) | 2011-07-27 |
| US20080207630A1 (en) | 2008-08-28 |
| ES2328405T3 (es) | 2009-11-12 |
| PL1874748T3 (pl) | 2010-01-29 |
| BRPI0608783A2 (pt) | 2010-01-26 |
| WO2006113376A1 (en) | 2006-10-26 |
| MX2007012703A (es) | 2008-01-14 |
| AU2006236714A1 (en) | 2006-10-26 |
| CN101160297A (zh) | 2008-04-09 |
| DE602006008447D1 (de) | 2009-09-24 |
| KR20070119088A (ko) | 2007-12-18 |
| US20110183955A1 (en) | 2011-07-28 |
| EP1874748A1 (de) | 2008-01-09 |
| US7932255B2 (en) | 2011-04-26 |
| JP2008536861A (ja) | 2008-09-11 |
| CA2604821A1 (en) | 2006-10-26 |
| PT1874748E (pt) | 2009-10-28 |
| RU2007141578A (ru) | 2009-05-20 |
| EP1874748B1 (de) | 2009-08-12 |
| DE102005017116A1 (de) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE439355T1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
| NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| EA200701467A1 (ru) | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
| ATE472529T1 (de) | Prolinamidderivate als natriumkanalmodulatoren | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| EA200801011A1 (ru) | Производные пиразина как модуляторы натриевых каналов для лечения боли | |
| BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
| MX2008007195A (es) | Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas. | |
| UA95930C2 (uk) | Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування | |
| DE502005010237D1 (de) | Stabile dosierungsform von phenylalanin-derivaten | |
| EA201990219A3 (ru) | Ингибиторы mek и способы их применения | |
| UA96742C2 (en) | Mek inhibitors and use thereof | |
| EA201791835A2 (ru) | Ингибиторы протеасом |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1874748 Country of ref document: EP |